PBS Biotech, a leading provider of innovative single-use bioreactor systems and bioprocess development services, has announced the appointment of Martin Simonetti as Chief Executive Officer, effective October 27, 2025. Simonetti brings over 40 years of experience in the biotechnology industry, including executive leadership, strategic financing, and managing large-scale pharmaceutical collaborations. As part of the company’s leadership transition, PBS founder Dr. Brian Lee will shift to the role of Chief Technology Officer, focusing on technology strategy and product innovation while remaining Chairman of the Board.
Health Technology Insights: Lyric Health, Curaechoice Partner for Free Virtual Care
Dr. Brian Lee, Founder, CTO, and Chairman of PBS Biotech, expressed his enthusiasm, stating that Simonetti’s strategic vision and operational expertise make him the ideal leader to guide PBS through its next growth phase. He highlighted Simonetti’s capability to expand PBS’s reach and reinforce its position as a trusted partner for cell and gene therapy companies working to transform patient care.
Martin Simonetti commented on his new role, emphasizing PBS Biotech’s reputation as an innovator in bioreactor technology and biomanufacturing processes. He noted that the company is well-positioned to strengthen its leadership in the rapidly expanding cell therapy market. Having served on the PBS Advisory Board for nearly ten years, Simonetti said he is honored to lead the company and work with Dr. Lee and the team to scale PBS’s impact as demand for advanced bioprocessing solutions grows, helping customers bring scientific breakthroughs to patients.
Health Technology Insights: Samsung Health and HealthTap Expand Access to Virtual Primary Care to Millions
Simonetti’s career spans executive roles at global life sciences companies and emerging biotech ventures. He previously served as President and CEO of VLST Corporation and held senior financial positions at Dendreon Corporation. His earlier experience includes leadership roles at Amgen, overseeing operations and finance, and research and finance roles at Genentech. Simonetti also serves on the boards of Curtana Pharmaceuticals and Eisana Corp. He holds an M.S. from the University of California, Davis, and an M.B.A. from Santa Clara University.
PBS Biotech continues to be backed by leading investors, including Avego, a healthcare-focused multi-strategy investment firm, and BroadOak, a boutique financial institution specializing in life sciences, positioning the company for sustained innovation and growth in the bioprocessing industry.
Health Technology Insights: Lirio Launches Behavioral Science Patient Engagement Tool
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
